Teleflex Buys Vascular Solutions For $1bn To Improve Growth
The purchase price of $56 a share in cash is a modest 16% premium over Vascular Solutions' 90-day average price. Vascular Solutions' CEO says uncertainty about the future leadership of the company compelled it to consider acquisition offers.
You may also be interested in...
Z-Medica’s wound care products, led by its QuikClot Control+ hemostatic dressing, complement Teleflex’s existing line of products marketed to first responders and the military.
US regulators have announced a second serious recall for a faulty catheter in the past month. The problem with Vascular Solutions’ catheter seems to be similar to Boston Scientific’s recall earlier this month, where a part of the device may break off and get stuck in the patient.
Teleflex is forking out over $1bn for privately held NeoTract. The latter has seen its revenues grow rapidly due to market enthusiasm for its UroLift system for treating lower urinary tract symptoms related to benign prostatic hyperplasia.